Galapagos to present GLPG0634 at ACR

| Source: Galapagos NV

MECHELEN, Belgium, Oct. 16, 2013 (GLOBE NEWSWIRE) --

Galapagos  NV (Euronext:  GLPG) announced
today that the Company will present data on the pharmacodynamics and efficacy of
its   selective  JAK1  inhibitor  GLPG0634  at  the  ACR  (American  College  of
Rheumatology)  which will take  place from 25-30 October  2013 in San Diego, CA,
US.  The abstracts are now available online on the ACR website.

Analysis  of  the  JAK1  selectivity  of  GLPG0634  and  its  main metabolite in
different species, healthy volunteers and rheumatoid arthritis patients
Abstract # 478
Poster session - Sunday, October 27, 2013, 8.30 - 4.00 pm

An  active  metabolite  contributes  to  the  pharmacodynamics  and  efficacy of
GLPG0634, a selective JAK1 inhibitor
Abstract # 1795
Oral session - Monday, October 28, 2013, 4.30 - 6.00 pm

The  JAK1-selective  inhibitor  GLPG0634  is  safe  and  rapidly reduces disease
activity  in patients with moderate to severe rheumatoid arthritis; results of a
4-week dose ranging study
Abstract # 2381
Poster session - Tuesday, October 29, 2013, 8.30 - 4.00 pm

About candidate drug GLPG0634
GLPG0634  is  an  orally-available,  novel  Janus  kinase  (JAK)  inhibitor with
selectivity  for JAK1 developed  by Galapagos.  JAKs  are critical components of
signalling  mechanisms utilized  by a  number of  cytokines and  growth factors,
including  those  that  are  elevated  in  rheumatoid  arthritis  patients.  JAK
inhibitors have shown long-term efficacy in rheumatoid arthritis studies with an
early  onset of  action.  GLPG0634  differentiates from  other JAK inhibitors in
development  by specifically targeting JAK1, a  strategy which could result in a
better  efficacy and safety  profile.  GLPG0634 is  a fully proprietary program.
 Upon  successful completion of the Phase  2b studies in RA, AbbVie will license
the program and will assume sole responsibility for Phase 3 clinical development
and global manufacturing.  GLPG0634 is also being developed for Crohn's disease.

About Galapagos
Galapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with  a large pipeline of  five Phase 2 (two led  by GSK), one Phase 1, six pre-
clinical,  and  20 discovery  small-molecule  and  antibody  programs  in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
AbbVie  and Galapagos signed an agreement  in CF where they work collaboratively
to  develop and commercialize oral drugs that  address two mutations in the CFTR
gene,  the G551D and F508del mutation.  In the field of inflammation, AbbVie and
Galapagos   signed   a  worldwide  license  agreement  whereby  AbbVie  will  be
responsible  for  further  development  and  commercialization of GLPG0634 after
Phase  2B.  GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment  of rheumatoid arthritis and  potentially other inflammatory diseases,
currently  in  Phase  2B studies  in  RA  and  about to enter Phase 2 studies in
Crohn's  disease.  Galapagos has another selective  JAK1 inhibitor in Phase 2 in
lupus   and   psoriasis,   GSK2586184   (formerly   GLPG0778,   in-licensed   by
GlaxoSmithKline  in  2012).  GLPG0974  is  the  first  inhibitor  of  FFA2 to be
evaluated  clinically for the treatment  of IBD; this program  is currently in a
Proof-of-Concept  Phase  2 study.   GLPG1205  is  a first-in-class molecule that
targets  inflammatory disorders  and is  currently in  a First-in-Human Phase 1
The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and
Fidelta,  has around  800 employees and  operates facilities  in five countries,
with   global  headquarters  in  Mechelen,  Belgium.   Further  information  at:


Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions.  Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements.  Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements.  These forward-looking statements speak only as
of the date of publication of this document.  Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.

Galapagos to present GLPG0634 at ACR: